43 , 44 Notably, the associations between individual mutations or pathways and treatment outcomes were mostly marginally significant, reinforcing the concept that effective subtyping may require the integration of multiple genomic markers rather than relying on a single feature.
← all excerpts
Consolidative nivolumab versus observation in unresectable stage III non-small cell lung cancer patients following neoadjuvant nivolumab plus chemotherapy and concurrent chemoradiotherapy (CA209-7AL): a randomized clinical trial.
1
—
—